On October 13, 2016, TG Therapeutics announced that it filed an amended protocol with the Food and Drug Administration for its leukemia drug combination, GENUINE Phase 3 Trial, and revealed that it no longer benefits from its previously negotiated Special Protocol Assessment with the FDA. Following this news, TG Therapeutics, stock dropped about $0.38 per share to close at $6.85 on that same day.
If you are aware of any facts relating to this investigation, or if you purchased shares of TG Therapeutics, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/tgtx or by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-tg-therapeutics-inc-tgtx-300347453.html
SOURCE Bronstein, Gewirtz & Grossman, LLC